
-
Heineken sees beer sales dip but keeps profit outlook
-
China's Pan puzzled after shock 200m free exit at swimming worlds
-
Honkytonk Kenya: Africa's home of country music
-
Head of China's Shaolin Temple removed over embezzlement claims
-
Tunisia plastic collectors spread as economic, migration woes deepen
-
China's birthplace of kung fu rocked by embezzlement probe
-
Europe hopes for 'no surprises' as US weighs force withdrawals
-
France's long wait for Tour winner goes on but Thevenet sees hope
-
Most markets rise, euro boosted after EU strikes US trade deal
-
US tariff tussles stuff of nightmares for Bordeaux winemakers
-
Taiwan's garbage trucks offer classical music and a catch-up
-
Thailand and Cambodia truce talks due but strikes continue
-
De Minaur battles to DC Open crown
-
US-China set to meet with extension of tariff pause on the cards
-
What is the status of US tariff negotiations?
-
State of play in Trump's tariffs, threats and delays
-
UN tackles beleaguered two-state solution for Israel, Palestinians
-
Wallabies call up former All Black prop Ross for third Lions Test
-
Australia rugby boss seeks answers on controversial Lions try
-
Monfils says Toronto loss marks his final Toronto visit
-
Toronto top seed Zverev got expert insight from retired rival Rafa
-
Kitayama captures PGA 3M Open title with big birdie weekend
-
George Lucas brings the force to Comic-Con in historic first visit
-
Palou wins eighth IndyCar title of year at Monterey Grand Prix
-
Three things we learned from the fourth Test between England and India
-
England hero Kelly overcomes 'dark moments' on way to Euro 2025 glory
-
Three dead, several injured after train derails in Germany
-
What we know so far about the EU-US trade deal
-
Spain deserved better in Euro 2025 final, says coach
-
King Charles salutes Lionesses after England's historic Euro glory
-
Stokes ready to 'run through brick wall' to feature in India decider
-
Fernandez dominates Kalinskaya to win DC Open
-
Wiegman hails 'incredible' Euros repeat for England
-
Bumrah playing in England finale would be 'great deal' for India says skipper Gill
-
Defending champions England beat Spain on penalties to win Women's Euro 2025
-
Four-time Tour de France winner Pogacar - greatest cyclist of his generation
-
Hundreds demonstrate in protest-hit UK town
-
Verstappen and Hamilton unhappy with 'overcautious' rain delay at Spa
-
Israel seeking to deport activists detained on Gaza-bound boat: NGO
-
'Fantastic Four' wins battle of heroes at N. America box office
-
Supreme Pogacar wins Tour de France for fourth time
-
Verstappen accuses race organisers of being overcautious with rain delay
-
Sundar and Jadeja follow Gill's lead as defiant India draw fourth Test with England
-
Piastri turns personal disappointment into motivation to win at Spa
-
Bayern agree deal to sign Liverpool winger Diaz: reports
-
WHO says malnutrition reaching 'alarming levels' in Gaza
-
Russia's Egorian wins world fencing gold as neutral athlete
-
Greece wildfires abating as firefighters contain outbreaks
-
Competitive element of Tour de France final stage removed after rain
-
Piastri holds off Norris at Spa, extends championship lead
SCU | 0% | 12.72 | $ | |
RBGPF | -1.52% | 73.88 | $ | |
SCS | 0.66% | 10.58 | $ | |
GSK | -0.68% | 37.97 | $ | |
RIO | -1.16% | 63.1 | $ | |
NGG | -0.11% | 72.15 | $ | |
RYCEF | -0.3% | 13.2 | $ | |
VOD | -0.79% | 11.43 | $ | |
RELX | -1.86% | 52.73 | $ | |
CMSD | 0.17% | 22.89 | $ | |
CMSC | 0.24% | 22.485 | $ | |
JRI | -0.46% | 13.09 | $ | |
BCC | 1.94% | 88.14 | $ | |
BCE | -0.95% | 24.2 | $ | |
AZN | -1.4% | 72.66 | $ | |
BP | 0.22% | 32.2 | $ | |
BTI | -0.71% | 52.25 | $ |

US limits Covid boosters to over-65s or those at high risk
The United States will limit Covid-19 boosters to people over 65 or those at risk of serious illness, while requiring vaccine makers to run fresh clinical trials before offering shots to younger and healthier individuals, officials said Tuesday.
Writing in the New England Journal of Medicine, the Food and Drug Administration's Vinayak Prasad and Commissioner Martin Makary framed the policy shift as "evidence-based" and would align the United States more closely with guidance in Europe.
But it comes as Health Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic, pushes to remake federal public health policy.
Kennedy previously led a nonprofit that was critical of immunization programs, and during the pandemic petitioned the FDA to revoke Covid vaccine authorizations, citing rare side effects including heart inflammation.
Prasad and Makary praised the initial Covid-19 vaccine rollout as "a major scientific, medical, and regulatory accomplishment," but argued that the benefits of repeated boosters for low-risk individuals are uncertain.
They criticized the US approach of recommending boosters for all adults regardless of age or health status, calling it a "one-size-fits-all" model based on the mistaken belief that Americans couldn't handle more nuanced, risk-based advice.
Rather than building public trust, they wrote, it had backfired -- fueling vaccine hesitancy that has spilled over into skepticism toward childhood shots, including those for measles.
The FDA said it would rely on lab test results to approve boosters for people who are over 65, or over six months old with at least one underlying condition.
But for healthy individuals between six months and 64 years, regulators will now require data from randomized trials.
"We simply don't know whether a healthy 52-year-old woman with a normal BMI (body mass index) who has had Covid-19 three times and has received six previous doses of a Covid-19 vaccine will benefit from the seventh dose," they wrote.
Some infectious disease experts welcomed the shift.
Amesh Adalja of Johns Hopkins University said it matched with the approach taken by other countries in a population that already carries significant immunity.
"For lower-risk individuals, the goal has always been less clear, as protection against infection is transient and they don't have a high risk of severe disease," he told AFP.
But others voiced concern about the practical consequences. Paul Offit, a leading vaccine expert at the Children's Hospital of Philadelphia, said it could limit access for people who still want boosters.
"Any use, say in a healthy 35-year-old, would be considered off-label, and you wonder whether an insurance company would pay for it," he told AFP.
- Not like annual flu shot -
Under the revised framework, companies like Pfizer and Moderna will be encouraged to test updated boosters in adults aged 50 to 64.
These studies should measure whether the vaccines reduce symptomatic infections, hospitalizations and deaths.
Rather than comparing new shots to earlier formulations, Prasad and Makary suggested placebo-controlled trials -- with saline as the comparator -- to better evaluate both benefit and potential side effects.
The proposal, first floated by Kennedy earlier this month, has proved divisive. Critics argue that using a placebo -- when authorized vaccines already exist -- could expose participants to unnecessary harm.
"Imagine if there was a death or two in the placebo group," said Offit. "I don't see how you conscience that."
Supporters of continued Covid-19 boosters often draw parallels to annual flu shots.
But Makary and Prasad pushed back on that comparison, arguing the genetic changes in Covid variants haven’t been significant enough to justify automatically updating the vaccine each year.
The FDA officials also sought to reassure Americans concerned they might lose access to boosters under the new framework.
The Centers for Disease Control and Prevention's (CDC) definition of risk factors is "vast, including obesity and even mental health conditions such as depression," they wrote, noting that between 100 million and 200 million Americans would likely still qualify.
N.Mitchell--AT